患者來源異種移植模型市場：按模型類型、移植方法、腫瘤類型、應用、最終用戶和地區分類。

預計到 2026 年，患者來源的異種移植模型市場規模將達到 1.75 億美元，到 2033 年將達到 5.809 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 18.7%。

全球患者來源異種移植模型市場涵蓋多種模型類型，包括細胞株來源模型、患者來源類器官、基因工程模型以及其他模型（如原代細胞來源模型、細胞處理模型等），並應用於胃腸道腫瘤模型、婦科腫瘤模型、呼吸系統腫瘤模型及其他腫瘤模型等領域。市場需求主要受製藥和生物技術公司以及委外研發機構(CRO) 的採用以及對更有效率、更可靠解決方案的需求所驅動。持續的技術進步和不斷成長的終端用戶需求正在推動該市場的成長。

市場動態：

胃腸道和婦科腫瘤模型應用範圍的擴大、終端用戶需求的成長以及對提高效率和性能的持續關注，預計將成為全球患者來源異種移植模型市場成長的主要驅動力。豐富的可用選項也使得更廣泛的使用者群體能夠使用這些解決方案。

例如，各公司正在拓展產品系列，以滿足製藥、生技公司和合約研究機構（CRO）不斷變化的需求。此外，預計在預測期內，加大創新投入和整合新技術將為市場參與者創造新的成長機會。

本報告的主要特點

• 本報告揭示了各個細分市場的潛在商機，並描述了該市場中一系列有吸引力的投資提案。
• 此外，它還提供了有關市場促進因素和限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要公司採取的競爭策略的重要見解。
• 本節根據各種參數（公司概況、產品系列、主要趨勢、財務表現、策略等）對全球患者來源異種移植模型市場的主要公司進行介紹。
• 本報告中的見解將使負責人和企業經營團隊能夠就未來的產品發布、技術更新、市場擴張和行銷策略做出明智的決策。
• 《全球患者來源異種移植模型市場》報告面向該行業的眾多相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過分析全球患者來源異種移植模型市場中使用的各種策略矩陣來促進決策。

目錄

第1章：分析目標與假設

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章：市場動態、監管與趨勢分析

• 市場動態
  • 促進因素
    • 癌症研究的擴展
  • 抑制因子
    • PDX模型的局限性
  • 機會
    • 應用於免疫療法測試
• 影響分析
• 主要亮點
• 監管趨勢
• 產品上市及核准
• PEST分析
• 波特的分析
• 併購情景

第4章：病患來源異種移植模型市場：依模型類型分類（2021-2033 年）

• 腫瘤切除模型
• 細胞株衍生模型
• 患者來源的類器官
• 基因改造模型
• 其他（原代細胞衍生模型、細胞處理模型等）

第5章：病患來源異種移植模型市場：依移植方法分類（2021-2033 年）

• 皮下移植
• 整形外科移植
• 其他

第6章：病患來源異種移植模型市場：依腫瘤類型分類（2021-2033 年）

• 胃腸道腫瘤模型
• 婦科腫瘤模型
• 呼吸系統腫瘤模型
• 其他腫瘤模型

第7章：病患來源異種移植模型市場：依最終使用者分類（2021-2033 年）

• 製藥和生物技術公司
• CRO（委外研發機構）
• 學術和研究機構
• 其他

第8章：病人來源異種移植模型市場：按地區分類（2021-2033 年）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 西班牙
  • 法國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第9章 競爭情勢

• THE JACKSON LABORATORY
• Champions Oncology, Inc
• Charles River Laboratories
• Crown Bioscience
• Hera Biolabs
• Horizon Discovery Group
• Oncodesign
• Pharmatest Services
• Shanghai LIDE Biotech
• Aragen Life Sciences Ltd.
• Creative Animodel
• Urosphere
• Applied StemCell
• WuXi AppTec

第10章

• 分析方法
• 關於 Coherent Market Insights

Patient Derived Xenograft Model Market is estimated to be valued at USD 175.0 Mn in 2026 and is expected to reach USD 580.9 Mn by 2033, growing at a compound annual growth rate (CAGR) of 18.7% from 2026 to 2033.

The global patient derived xenograft model market covers a broad set of model type categories, including Cell line derived models, Patient derived organoids, and Genetically engineered models and Others (Primary cell derived models, cell processed models etc.), used across applications such as Gastrointestinal Tumor Model, Gynecological Tumor Model, and Respiratory Tumor Model and Other Tumor Model. Demand is supported by adoption among Pharmaceutical & Biotechnology Companies, and Contract Research Organizations (CROs) and the need for more efficient, reliable solutions. Continued technological advancement and rising end-user requirements are shaping the growth of this market.

Market Dynamics:

Growing adoption across Gastrointestinal Tumor Model, and Gynecological Tumor Model, rising end-user demand, and a continued focus on improving efficiency and performance are major factors expected to drive growth of the global patient derived xenograft model market. A wider range of available options is making these solutions accessible to a broader base of users.

For instance, companies are expanding their portfolios to address evolving requirements across Pharmaceutical & Biotechnology Companies, and Contract Research Organizations (CROs). Moreover, increasing investment in innovation and new technology integration is expected to create new growth opportunities for market players over the forecast period.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global patient derived xenograft model market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include THE JACKSON LABORATORY, Champions Oncology, Inc, Charles River Laboratories, Crown Bioscience, Hera Biolabs, Horizon Discovery Ltd., Oncodesign, Pharmatest Services, Shanghai LIDE Biotech, Aragen Life Sciences Ltd., Creative Animodel, Urosphere, and Applied StemCell and WuXi AppTec, among others.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global patient derived xenograft model market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global patient derived xenograft model market.

Detailed Segmentation:

• Global Patient Derived Xenograft Model Market, By Model Type (Revenue, USD Bn, 2021 - 2033)
• Cell line derived models
• Patient derived organoids
• Genetically engineered models and Others (Primary cell derived models, cell processed models etc.)
• Global Patient Derived Xenograft Model Market, By Implantation Method (Revenue, USD Bn, 2021 - 2033)
• Subcutaneous Implantation
• Orthopedic Implantation and Others
• Global Patient Derived Xenograft Model Market, By Tumor Type (Revenue, USD Bn, 2021 - 2033)
• Blood Cancer Models
• Solid Tumor Models
• Pediatric Tumor Models
• Other Rare Tumor Models
• Combination PDX Models
• Custom PDX Models
• Others
• Global Patient Derived Xenograft Model Market, By Application (Revenue, USD Bn, 2021 - 2033)
• Gastrointestinal Tumor Model
• Gynecological Tumor Model
• Respiratory Tumor Model and Other Tumor Model
• Global Patient Derived Xenograft Model Market, By End User (Revenue, USD Bn, 2021 - 2033)
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutions
• Others
• Regional Insights (Revenue, USD Bn, 2021 - 2033)
• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa
• Company Profiles:
• THE JACKSON LABORATORY*
  • Company Overview
  • Product Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategies
• Champions Oncology, Inc
• Charles River Laboratories
• Crown Bioscience
• Hera Biolabs
• Horizon Discovery Ltd.
• Oncodesign
• Pharmatest Services
• Shanghai LIDE Biotech
• Aragen Life Sciences Ltd.
• Creative Animodel
• Urosphere
• Applied StemCell and WuXi AppTec

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Patient Derived Xenograft Model, By Model Type
  • Market Patient Derived Xenograft Model, By Implantation Method
  • Market Patient Derived Xenograft Model, By Tumor Type
  • Market Patient Derived Xenograft Model, By End User
  • Market Patient Derived Xenograft Model, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
    • Increasing Cancer Research
  • Restraints
    • Limitations of PDX Models
  • Opportunities
    • Applications in Immunotherapy Testing
• Impact Analysis
• Key Highlights
• Regulatory Scenario
• Product launch/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario

4. Patient Derived Xenograft Model Market , By Model Type, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Tumor explant models
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Cell line derived models
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Patient derived organoids
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Genetically engineered models
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Others (Primary cell derived models, cell processed models etc.)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

5. Patient Derived Xenograft Model Market , By Implantation Method, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2026 and 2033 (%)
  • Y-o-Y Growth Analysis, 2022 - 2033
  • Segment Trends
• Subcutaneous Implantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Orthopedic Implantation
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Mn)

6. Patient Derived Xenograft Model Market , By Tumor Type, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
• Gastrointestinal Tumor Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Gynecological Tumor Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Respiratory Tumor Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Other Tumor Model
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)

7. Patient Derived Xenograft Model Market , By End User, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, 2023and 2033 (%)
  • Y-o-Y Growth Analysis, 2022- 2033
  • Segment Trends
• Pharmaceutical & Biotechnology Companies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Contract Research Organizations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Academic & Research Institutions
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Million)

8. Patient Derived Xenograft Model Market , By Region, 2021 - 2033, (US$ Mn)

• Introduction
  • Market Share Analysis, By Country, 2023and 2033 (%)
  • Y-o-Y Growth Analysis, For Country 2022-2033
  • Country Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • U.S.
    • Canada
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Model Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Implantation Method, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Tumor Type, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Mn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033,(US$ Mn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• THE JACKSON LABORATORY
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Champions Oncology, Inc
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Charles River Laboratories
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Crown Bioscience
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Hera Biolabs
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Horizon Discovery Group
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Oncodesign
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Pharmatest Services
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Shanghai LIDE Biotech
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Aragen Life Sciences Ltd.
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Creative Animodel
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Urosphere
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Applied StemCell
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• WuXi AppTec
  • Company Highlights
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
• Analyst Views

10. Section

• Research Methodology
• About us